Citius Pharmaceuticals Inc Share Price Today: Live Updates & Key Insights

Citius Pharmaceuticals Inc share price today is $0.786, up -5.15%. The stock opened at $0.78505 against the previous close of $0.8124, with an intraday high of $0.8003 and low of $0.7472.

Citius Pharmaceuticals Inc Share Price Chart

Citius Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
us-stock

Citius Pharmaceuticals Inc Share Price Performance

$0.786 -0.0515(-5.15%) CTXR at 23 Mar 2026 12:36 PM Biotechnology
Lowest Today 0.7472
Highest Today 0.8003
Today’s Open 0.78505
Prev. Close 0.8124
52 Week High 2.48
52 Week Low 0.63
Day’s Range: Low 0.7472 High 0.8003
52-Week Range: Low 0.63 High 2.48
1 day return -
1 Week return -13.94
1 month return +15.15
3 month return -27.4
6 month return -34.53
1 year return -46.81
3 year return -23.07
5 year return -61.12
10 year return -

Citius Pharmaceuticals Inc Institutional Holdings

Heights Capital Management Inc 3.57

Vanguard Group Inc 0.89

Geode Capital Management, LLC 0.57

Vanguard Institutional Extnd Mkt Idx Tr 0.54

Fidelity Extended Market Index 0.39

BlackRock Inc 0.31

Abante Quant Value FI 0.29

Two Sigma Investments LLC 0.27

Asset Advisory Group, INC. 0.26

NT Ext Equity Mkt Idx Fd - L 0.17

TWO SIGMA SECURITIES, LLC 0.13

Northern Trust Corp 0.12

UBS Group AG 0.12

LPL Financial Corp 0.11

State Street Corp 0.10

Northern Trust Extended Eq Market Idx 0.10

Arkadios Wealth Advisors 0.09

Jane Street Group LLC 0.08

Fidelity Series Total Market Index 0.07

XTX Topco Ltd 0.07

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.07

Susquehanna International Group, LLP 0.06

Spartan Total Market Index Pool G 0.05

Fidelity Total Market Index 0.05

Blackrock Extended Mkt Fund CF 0.05

SIMPLEX TRADING, LLC 0.04

Extended Equity Market Fund K 0.04

IFP Advisors, LLC 0.03

NT Ext Equity Mkt Idx Fd - NL 0.02

Chelsea Management Company 0.02

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.02

SBI Securities Co Ltd 0.02

Tower Research Capital LLC 0.01

State St US Extended Mkt Indx NL Cl C 0.01

Vanguard U.S. Eq Idx £ Acc 0.01

Extended Equity Market Fund M 0.00

SSgA U.S. Total Market Index Strategy 0.00

Spartan Extended Market Index Pool F 0.00

State St US Ttl Mkt Indx NL Cl A 0.00

Northern Trust Wilshire 5000 0.00

Citius Pharmaceuticals Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Citius Pharmaceuticals Inc Fundamentals

Market Cap 17.24 M

PB Ratio 0.2125

PE Ratio 0.0

Enterprise Value 11.10 M

Total Assets 130.94 M

Volume 393560

Citius Pharmaceuticals Inc Company Financials

Annual Revenue FY25:0 0.0M, FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M

Annual Profit FY25:-214250 -0.2M, FY24:null 0.0M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M

Annual Net worth FY25:-37433911 -37.4M, FY24:-39425839 -39.4M, FY23:-32542912 -32.5M, FY22:-33640646 -33.6M, FY21:-23125190 -23.1M

Quarterly Revenue Q4/2025:3944111 3.9M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q4/2024:155926 0.2M

Quarterly Profit Q4/2025:2581465 2.6M, Q3/2025:-62038 -0.1M, Q2/2025:-41367 -0.0M, Q1/2025:-56010 -0.1M, Q4/2024:null 0.0M

Quarterly Net worth Q4/2025:-8220784 -8.2M, Q3/2025:-7959288 -8.0M, Q2/2025:-8789872 -8.8M, Q1/2025:-10916505 -10.9M, Q4/2024:-9768246 -9.8M

About Citius Pharmaceuticals Inc & investment objective

Company Information Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Organisation Biotechnology

Employees 23

Industry Biotechnology

CEO Mr. Leonard L. Mazur

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Citius Pharmaceuticals Inc FAQs

What is the share price of Citius Pharmaceuticals Inc today?

The current share price of Citius Pharmaceuticals Inc is $0.786.

Can I buy Citius Pharmaceuticals Inc shares in India?

Yes, Indian investors can buy Citius Pharmaceuticals Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Citius Pharmaceuticals Inc shares in India?

You can easily invest in Citius Pharmaceuticals Inc shares from India by:

Can I buy fractional shares of Citius Pharmaceuticals Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Citius Pharmaceuticals Inc?

Citius Pharmaceuticals Inc has a market cap of $17.24 M.

In which sector does Citius Pharmaceuticals Inc belong?

Citius Pharmaceuticals Inc operates in the Biotechnology sector.

What documents are required to invest in Citius Pharmaceuticals Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Citius Pharmaceuticals Inc?

The PE ratio of Citius Pharmaceuticals Inc is N/A and the PB ratio is 0.21.